Cargando…
Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine
Schistosomiasis, a disease historically associated with poverty, lack of sanitation and social inequality, is a chronic, debilitating parasitic infection, affecting hundreds of millions of people in endemic countries. Although chemotherapy is capable of reducing morbidity in humans, rapid re-infecti...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306874/ https://www.ncbi.nlm.nih.gov/pubmed/30469320 http://dx.doi.org/10.3390/tropicalmed3040121 |
_version_ | 1783382877351706624 |
---|---|
author | Tendler, Miriam Almeida, Marília S. Vilar, Monica M. Pinto, Patrícia M. Limaverde-Sousa, Gabriel |
author_facet | Tendler, Miriam Almeida, Marília S. Vilar, Monica M. Pinto, Patrícia M. Limaverde-Sousa, Gabriel |
author_sort | Tendler, Miriam |
collection | PubMed |
description | Schistosomiasis, a disease historically associated with poverty, lack of sanitation and social inequality, is a chronic, debilitating parasitic infection, affecting hundreds of millions of people in endemic countries. Although chemotherapy is capable of reducing morbidity in humans, rapid re-infection demonstrates that the impact of drug treatment on transmission control or disease elimination is marginal. In addition, despite more than two decades of well-executed control activities based on large-scale chemotherapy, the disease is expanding in many areas including Brazil. The development of the Sm14/GLA-SE schistosomiasis vaccine is an emblematic, open knowledge innovation that has successfully completed phase I and phase IIa clinical trials, with Phase II/III trials underway in the African continent, to be followed by further trials in Brazil. The discovery and experimental phases of the development of this vaccine gathered a robust collection of data that strongly supports the ongoing clinical phase. This paper reviews the development of the Sm14 vaccine, formulated with glucopyranosyl lipid A (GLA-SE), from the initial experimental developments to clinical trials including the current status of phase II studies. |
format | Online Article Text |
id | pubmed-6306874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63068742019-01-02 Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine Tendler, Miriam Almeida, Marília S. Vilar, Monica M. Pinto, Patrícia M. Limaverde-Sousa, Gabriel Trop Med Infect Dis Review Schistosomiasis, a disease historically associated with poverty, lack of sanitation and social inequality, is a chronic, debilitating parasitic infection, affecting hundreds of millions of people in endemic countries. Although chemotherapy is capable of reducing morbidity in humans, rapid re-infection demonstrates that the impact of drug treatment on transmission control or disease elimination is marginal. In addition, despite more than two decades of well-executed control activities based on large-scale chemotherapy, the disease is expanding in many areas including Brazil. The development of the Sm14/GLA-SE schistosomiasis vaccine is an emblematic, open knowledge innovation that has successfully completed phase I and phase IIa clinical trials, with Phase II/III trials underway in the African continent, to be followed by further trials in Brazil. The discovery and experimental phases of the development of this vaccine gathered a robust collection of data that strongly supports the ongoing clinical phase. This paper reviews the development of the Sm14 vaccine, formulated with glucopyranosyl lipid A (GLA-SE), from the initial experimental developments to clinical trials including the current status of phase II studies. MDPI 2018-11-21 /pmc/articles/PMC6306874/ /pubmed/30469320 http://dx.doi.org/10.3390/tropicalmed3040121 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tendler, Miriam Almeida, Marília S. Vilar, Monica M. Pinto, Patrícia M. Limaverde-Sousa, Gabriel Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine |
title | Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine |
title_full | Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine |
title_fullStr | Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine |
title_full_unstemmed | Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine |
title_short | Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine |
title_sort | current status of the sm14/gla-se schistosomiasis vaccine: overcoming barriers and paradigms towards the first anti-parasitic human(itarian) vaccine |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306874/ https://www.ncbi.nlm.nih.gov/pubmed/30469320 http://dx.doi.org/10.3390/tropicalmed3040121 |
work_keys_str_mv | AT tendlermiriam currentstatusofthesm14glaseschistosomiasisvaccineovercomingbarriersandparadigmstowardsthefirstantiparasitichumanitarianvaccine AT almeidamarilias currentstatusofthesm14glaseschistosomiasisvaccineovercomingbarriersandparadigmstowardsthefirstantiparasitichumanitarianvaccine AT vilarmonicam currentstatusofthesm14glaseschistosomiasisvaccineovercomingbarriersandparadigmstowardsthefirstantiparasitichumanitarianvaccine AT pintopatriciam currentstatusofthesm14glaseschistosomiasisvaccineovercomingbarriersandparadigmstowardsthefirstantiparasitichumanitarianvaccine AT limaverdesousagabriel currentstatusofthesm14glaseschistosomiasisvaccineovercomingbarriersandparadigmstowardsthefirstantiparasitichumanitarianvaccine |